Alternative chemoradiotherapy in anal carcinoma patients with mutations in thymidylate synthase and dihydropyrimidine dehydrogenase genes

BACKGROUND: 5-fluorouracil (5-FU) and mitomycin-C (MMC) with radiotherapy (RT) remain an established treatment for patients with anal cancer (AC). Genetic mutations in two major metabolizing enzymes for 5-FU; dihydropyrimidine dehydrogenase (DPYD and thymidylate synthetase (TYMS), have been associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Saif, MW, Hamal, Ruchi, Siddiqui, Nauman, Maloney, Antonia, Smith, Melissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Advances and Future Perspectives in Colorectal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255561/
https://www.ncbi.nlm.nih.gov/pubmed/34276810
http://dx.doi.org/10.1177/17562848211024464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255561/
https://www.ncbi.nlm.nih.gov/pubmed/34276810
http://dx.doi.org/10.1177/17562848211024464

Ejemplares similares